These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34224592)

  • 41. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.
    Singel KL; Emmons TR; Khan ANH; Mayor PC; Shen S; Wong JT; Morrell K; Eng KH; Mark J; Bankert RB; Matsuzaki J; Koya RC; Blom AM; McLeish KR; Qu J; Ram S; Moysich KB; Abrams SI; Odunsi K; Zsiros E; Segal BH
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30730851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives.
    Rajkumari S; Singh J; Agrawal U; Agrawal S
    Int Immunopharmacol; 2024 Dec; 142(Pt A):112949. PubMed ID: 39236460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
    Joshi S; Sharabi A
    Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients.
    Bruderek K; Schirrmann R; Brandau S
    Methods Mol Biol; 2021; 2236():1-7. PubMed ID: 33237535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.
    Susek KH; Karvouni M; Alici E; Lundqvist A
    Front Immunol; 2018; 9():2159. PubMed ID: 30319622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment.
    Agresta L; Hoebe KHN; Janssen EM
    Front Immunol; 2018; 9():2809. PubMed ID: 30546369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
    Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-33 in Malignancies: Friends or Foes?
    Shen JX; Liu J; Zhang GJ
    Front Immunol; 2018; 9():3051. PubMed ID: 30619376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).
    Alfaro C; Teijeira A; Oñate C; Pérez G; Sanmamed MF; Andueza MP; Alignani D; Labiano S; Azpilikueta A; Rodriguez-Paulete A; Garasa S; Fusco JP; Aznar A; Inogés S; De Pizzol M; Allegretti M; Medina-Echeverz J; Berraondo P; Perez-Gracia JL; Melero I
    Clin Cancer Res; 2016 Aug; 22(15):3924-36. PubMed ID: 26957562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
    Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
    J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
    Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors.
    Dahal A; Hong Y; Mathew JS; Geber A; Eckl S; Renner S; Sailer CJ; Ryan AT; Mir S; Lim K; Linehan DC; Gerber SA; Kim M
    Proc Natl Acad Sci U S A; 2024 Aug; 121(35):e2406748121. PubMed ID: 39178229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Myeloid-Derived Suppressor Cells in Cancer.
    Anani W; Shurin MR
    Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.